Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Terns has had a successful year in 2025 and anticipates continued excitement in 2026, with the potential to become a best-in-disease therapy in the CML market [3] - The company has demonstrated unprecedented efficacy along with a strong safety and tolerability profile, positioning itself for the next generation of CML therapies [3] - Terns plans to engage with the FDA to discuss trial design and aims to initiate second-line and first-line trials promptly [4] Financial Position - Terns currently holds $1 billion in cash on its balance sheet, providing a strong financial foundation for upcoming trials and initiatives [4]